BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 29774366)

  • 21. Genetic variations of patients with familial or multiple melanoma in Southern Brazil.
    Grazziotin TC; Rey MC; Bica CG; Pinto LA; Bonamigo RR; Puig-Butille JA; Cuellar F; Puig S
    J Eur Acad Dermatol Venereol; 2013 Feb; 27(2):e179-85. PubMed ID: 22621339
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Histologic features of melanoma associated with germline mutations of CDKN2A, CDK4, and POT1 in melanoma-prone families from the United States, Italy, and Spain.
    Sargen MR; Calista D; Elder DE; Massi D; Chu EY; Potrony M; Pfeiffer RM; Carrera C; Aguilera P; Alos L; Puig S; Elenitsas R; Yang XR; Tucker MA; Landi MT; Goldstein AM
    J Am Acad Dermatol; 2020 Sep; 83(3):860-869. PubMed ID: 32283231
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations.
    Goldstein AM; Struewing JP; Chidambaram A; Fraser MC; Tucker MA
    J Natl Cancer Inst; 2000 Jun; 92(12):1006-10. PubMed ID: 10861313
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of melanoma susceptibility genes in high-risk patients from Central Italy.
    Pellegrini C; Maturo MG; Martorelli C; Suppa M; Antonini A; Kostaki D; Verna L; Landi MT; Peris K; Fargnoli MC
    Melanoma Res; 2017 Jun; 27(3):258-267. PubMed ID: 28146043
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CDKN2A/CDK4 status in Brazilian patients meeting clinical criteria for hereditary melanoma: a cross-sectional descriptive trial.
    Arnaut JRMB; Guimarães IDS; Dos Santos ACE; Rodrigues EM; Machado JRDS; de Melo AC
    Int J Dermatol; 2023 Aug; 62(8):1060-1066. PubMed ID: 37322831
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of individuals at high risk of developing melanoma in Latin America: bases for genetic counseling in melanoma.
    Puig S; Potrony M; Cuellar F; Puig-Butille JA; Carrera C; Aguilera P; Nagore E; Garcia-Casado Z; Requena C; Kumar R; Landman G; Costa Soares de Sá B; Gargantini Rezze G; Facure L; de Avila AL; Achatz MI; Carraro DM; Duprat Neto JP; Grazziotin TC; Bonamigo RR; Rey MC; Balestrini C; Morales E; Molgo M; Bakos RM; Ashton-Prolla P; Giugliani R; Larre Borges A; Barquet V; Pérez J; Martínez M; Cabo H; Cohen Sabban E; Latorre C; Carlos-Ortega B; Salas-Alanis JC; Gonzalez R; Olazaran Z; Malvehy J; Badenas C
    Genet Med; 2016 Jul; 18(7):727-36. PubMed ID: 26681309
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Population-based prevalence of CDKN2A and CDK4 mutations in patients with multiple primary melanomas.
    Helsing P; Nymoen DA; Ariansen S; Steine SJ; Maehle L; Aamdal S; Langmark F; Loeb M; Akslen LA; Molven A; Andresen PA
    Genes Chromosomes Cancer; 2008 Feb; 47(2):175-84. PubMed ID: 18023021
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genomic rearrangements of the CDKN2A locus are infrequent in Italian malignant melanoma families without evidence of CDKN2A/CDK4 point mutations.
    Vignoli M; Scaini MC; Ghiorzo P; Sestini R; Bruno W; Menin C; Gensini F; Piazzini M; Testori A; Manoukian S; Orlando C; D'Andrea E; Bianchi-Scarrà G; Genuardi M
    Melanoma Res; 2008 Dec; 18(6):431-7. PubMed ID: 19011513
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiple melanomas after treatment for Hodgkin lymphoma in a non-Dutch p16-Leiden mutation carrier with 2 MC1R high-risk variants.
    Figl A; Thirumaran RK; Ugurel S; Gast A; Hemminki K; Kumar R; Schadendorf D
    Arch Dermatol; 2007 Apr; 143(4):495-9. PubMed ID: 17438182
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CDKN2a mutation-negative melanoma families have increased risk exclusively for skin cancers but not for other malignancies.
    Helgadottir H; Höiom V; Tuominen R; Jönsson G; Månsson-Brahme E; Olsson H; Hansson J
    Int J Cancer; 2015 Nov; 137(9):2220-6. PubMed ID: 25943250
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low prevalence of germline CDKN2A and CDK4 mutations in patients with early-onset melanoma.
    Tsao H; Zhang X; Kwitkiwski K; Finkelstein DM; Sober AJ; Haluska FG
    Arch Dermatol; 2000 Sep; 136(9):1118-22. PubMed ID: 10987867
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CDKN2A and MC1R analysis in amelanotic and pigmented melanoma.
    Ghiorzo P; Pastorino L; Pizzichetta MA; Bono R; Queirolo P; Talamini R; Annessi G; Bruno W; Nasti S; Gargiulo S; Battistuzzi L; Sini MC; Palmieri G; Scarrà GB;
    Melanoma Res; 2009 Jun; 19(3):142-5. PubMed ID: 19339902
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improvement of Genetic Testing for Cutaneous Melanoma in Countries With Low to Moderate Incidence: The Rule of 2 vs the Rule of 3.
    Delaunay J; Martin L; Bressac-de Paillerets B; Duru G; Ingster O; Thomas L
    JAMA Dermatol; 2017 Nov; 153(11):1122-1129. PubMed ID: 28903138
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early onset may predict G101W CDKN2A founder mutation carrier status in Ligurian melanoma patients.
    Mantelli M; Pastorino L; Ghiorzo P; Barile M; Bruno W; Gargiulo S; Sormani MP; Gliori S; Vecchio S; Ciotti P; Sertoli MR; Queirolo P; Goldstein AM; Bianchi-Scarrà G;
    Melanoma Res; 2004 Dec; 14(6):443-8. PubMed ID: 15577313
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Capturing the biological impact of CDKN2A and MC1R genes as an early predisposing event in melanoma and non melanoma skin cancer.
    Puig-Butille JA; Escámez MJ; Garcia-Garcia F; Tell-Marti G; Fabra À; Martínez-Santamaría L; Badenas C; Aguilera P; Pevida M; Dopazo J; del Río M; Puig S
    Oncotarget; 2014 Mar; 5(6):1439-51. PubMed ID: 24742402
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MC1R variants predisposing to concomitant primary cutaneous melanoma in a monozygotic twin pair.
    Pellegrini C; Fargnoli MC; Suppa M; Peris K
    BMC Med Genet; 2012 Sep; 13():81. PubMed ID: 22978401
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Variation in Cutaneous Patterns of Melanomagenesis According to Germline CDKN2A/CDK4 Status in Melanoma-Prone Families.
    Sargen MR; Pfeiffer RM; Yang XR; Tucker MA; Goldstein AM
    J Invest Dermatol; 2020 Jan; 140(1):174-181.e3. PubMed ID: 31326397
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cancer risks and survival in patients with multiple primary melanomas: Association with family history of melanoma and germline CDKN2A mutation status.
    Helgadottir H; Tuominen R; Olsson H; Hansson J; Höiom V
    J Am Acad Dermatol; 2017 Nov; 77(5):893-901. PubMed ID: 28818438
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High- and intermediate-risk susceptibility variants in melanoma families from the Mediterranean area: A multicentre cohort from the MelaNostrum Consortium.
    Pellegrini C; Cardelli L; Ghiorzo P; Pastorino L; Potrony M; García-Casado Z; Elefanti L; Stefanaki I; Mastrangelo M; Necozione S; Aguilera P; Rodríguez-Hernández A; Di Nardo L; Rocco T; Del Regno L; Badenas C; Carrera C; Malvehy J; Requena C; Bañuls J; Stratigos AJ; Peris K; Menin C; Calista D; Nagore E; Puig S; Landi MT; Fargnoli MC
    J Eur Acad Dermatol Venereol; 2023 Dec; 37(12):2498-2508. PubMed ID: 37611275
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Skin Pigmentation Genetics for the Clinic.
    Ainger SA; Jagirdar K; Lee KJ; Soyer HP; Sturm RA
    Dermatology; 2017; 233(1):1-15. PubMed ID: 28463841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.